Pimozide-d_4

Cat. No.:	HY-12987S
CAS No.:	1803193-57-8
Molecular Formula:	$C_{28}H_{25}D_4F_2N_3O$
Molecular Weight:	465.57
Target:	Dopamine Receptor; Adrenergic Receptor; STAT
Pathway:	GPCR/G Protein; Neuronal Signaling; JAK/STAT Signaling; Stem Cell/Wnt
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	Pimozide-d_4 is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3].			
IC_{50} & Target	Dopamine D2 receptor 1.4 nM (Ki)	opamine D3 receptor 2.5 nM (Ki)	opamine D1 receptor 588 nM (Ki)	α1-adrenoceptor 39 nM (Ki)
	STAT3	STAT5		

REFERENCES

[1]. Ybema CE, et al. Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol. 1994 Apr 21;256(2):141-7.

[2]. Cai N, et al. The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res. 2017 Aug 15;9(8):3853-3866. eCollection 2017.

[3]. Erik A. Nelson, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12): 3421-3429.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA